디지털 PCR 시장 - 예측(2026-2031년)

The digital PCR market is expected to expand at a 13.97% CAGR, reaching USD 2151.54 million in 2031 from USD 981.865 million in 2025.

The digital PCR (dPCR) market represents a significant technological advancement in molecular diagnostics and life science research, offering a level of precision and absolute quantification beyond traditional PCR methods. By partitioning a nucleic acid sample into thousands of individual reactions, dPCR enables the precise counting of target DNA or RNA molecules without the need for a standard curve. This paradigm shift towards absolute quantification is driving adoption in applications requiring high sensitivity and accuracy, including low-abundance mutation detection, copy number variation analysis, and validation of next-generation sequencing results. The market's expansion is fueled by the growing demand for precise genetic analysis in oncology, infectious disease monitoring, and advanced research, supported by continuous technological refinement.

A primary driver for market growth is the increasing prevalence of cancers and infectious diseases globally, which necessitates highly sensitive and specific diagnostic tools. In oncology, dPCR is particularly valuable for detecting rare mutations, monitoring minimal residual disease (MRD), and evaluating treatment response through liquid biopsy applications. Its ability to precisely quantify tumor DNA from a blood sample provides a less invasive method for longitudinal patient monitoring. Similarly, in infectious disease diagnostics, dPCR offers superior sensitivity for detecting low viral loads, quantifying pathogen levels with high accuracy, and distinguishing closely related strains. The clinical need for reliable, quantitative data to guide therapeutic decisions is elevating dPCR from a research tool to an integral component of precision medicine workflows.

Within the dPCR landscape, droplet digital PCR (ddPCR) technology is anticipated to hold a dominant market position. This method utilizes a water-oil emulsion system to partition samples into tens of thousands of nanoliter-sized droplets, each functioning as an independent PCR micro-reactor. The key advantages of ddPCR include its high degree of partitioning, robust resistance to PCR inhibitors present in complex samples, and exceptional precision for absolute quantification. These attributes make it especially suitable for challenging clinical applications such as detecting rare mutations in circulating tumor DNA or accurately measuring viral load. The commercialization of integrated, user-friendly ddPCR systems has been instrumental in translating this advanced technology from core research facilities into clinical diagnostic laboratories.

The clinical diagnostics segment represents a major and rapidly growing application area for dPCR. This growth is driven by the technology's superior accuracy, reproducibility, and sensitivity compared to quantitative PCR (qPCR). dPCR is increasingly employed for non-invasive prenatal testing (NIPT), oncology biomarker validation, and the detection of pathogens that are difficult to culture or present at very low concentrations. The trend toward personalized medicine and the need for robust assays that can deliver reliable results from limited or challenging sample types are accelerating its integration into diagnostic test development and routine clinical use.

Concurrently, the expanding scope of genetic engineering and genomic research is fostering a conducive environment for dPCR adoption. In academic and biopharmaceutical research, dPCR is essential for applications requiring absolute quantification, such as validating gene editing outcomes (e.g., CRISPR-Cas9), characterizing viral vector titers in gene therapy, and performing precise gene expression analysis. The technology's ability to provide unambiguous, copy-number data without external calibration makes it a gold-standard method for critical quality control steps in biomanufacturing and therapeutic development. The rising investment in genomic research and the development of cell and gene therapies are creating sustained demand for these high-precision analytical tools.

Geographically, North America is anticipated to maintain a leadership position in the dPCR market. This is attributed to the region's advanced healthcare infrastructure, high concentration of leading biotechnology and pharmaceutical companies, and substantial investment in genomic research. The presence of a sophisticated network of diagnostic laboratories that are early adopters of innovative technologies further supports market growth. A strong culture of precision medicine, coupled with significant research funding from both public and private sectors for cancer and infectious disease studies, creates a robust ecosystem for the development and clinical application of dPCR technologies.

The competitive landscape features established life science tool providers and specialized molecular diagnostics companies. Key players compete on the basis of instrument throughput, sensitivity, ease-of-use, and the development of integrated workflows that include proprietary reagents and analysis software. Strategic focus areas include expanding the menu of clinically validated assays, enhancing automation to streamline workflow in high-throughput settings, and forming partnerships with diagnostic labs and biopharmaceutical firms to co-develop application-specific solutions. Ongoing innovation is directed at improving multiplexing capabilities, reducing cost per sample, and enhancing data analysis pipelines to simplify interpretation for clinical users.

In conclusion, the digital PCR market is transitioning from a specialized research technology to a cornerstone of advanced molecular diagnostics. Its growth is fundamentally linked to the increasing demand for absolute quantification in both clinical and research settings, where its precision and sensitivity offer tangible advantages over conventional methods. The future trajectory of the market will be shaped by further integration into routine clinical pathways, the development of standardized diagnostic assays, and continued innovation to improve accessibility and throughput. As the emphasis on precise, data-driven healthcare intensifies, dPCR is poised to play an increasingly critical role in disease detection, monitoring, and the advancement of personalized therapeutic strategies.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Digital PCR Market Segmentation

• By Technology
• Droplet Digital PCR
• Chip Based Digital PCR
• Beaming Digital PCR
• By Application
• Clinical Diagnostics
• Forensic and Others
• Research
• By Product Type
• Digital PCR Systems
• Consumables and Reagents
• Software and Services
• By End-User
• Pharmaceuticals and Biotechnology Industries
• Clinical Diagnostic Laboratories
• Universities
• Others
• By Geography
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. DIGITAL PCR MARKET BY TECHNOLOGY

• 5.1. Introduction
• 5.2. Droplet Digital PCR
• 5.3. Chip Based Digital PCR
• 5.4. Beaming Digital PCR

6. DIGITAL PCR MARKET BY APPLICATION

• 6.1. Introduction
• 6.2. Clinical Diagnostics
• 6.3. Forensic and Others
• 6.4. Research

7. DIGITAL PCR MARKET BY PRODUCT TYPE

• 7.1. Introduction
• 7.2. Digital PCR Systems
• 7.3. Consumables and Reagents
• 7.4. Software and Services

8. DIGITAL PCR MARKET BY END-USER

• 8.1. Introduction
• 8.2. Pharmaceuticals and Biotechnology Industries
• 8.3. Clinical Diagnostic Laboratories
• 8.4. Universities
• 8.5. Others

9. DIGITAL PCR MARKET BY GEOGRAPHY

• 9.1. Introduction
• 9.2. North America
  • 9.2.1. USA
  • 9.2.2. Canada
  • 9.2.3. Mexico
• 9.3. South America
  • 9.3.1. Brazil
  • 9.3.2. Argentina
  • 9.3.3. Others
• 9.4. Europe
  • 9.4.1. Germany
  • 9.4.2. France
  • 9.4.3. United Kingdom
  • 9.4.4. Spain
  • 9.4.5. Others
• 9.5. Middle East and Africa
  • 9.5.1. Saudi Arabia
  • 9.5.2. UAE
  • 9.5.3. Others
• 9.6. Asia Pacific
  • 9.6.1. China
  • 9.6.2. India
  • 9.6.3. Japan
  • 9.6.4. South Korea
  • 9.6.5. Indonesia
  • 9.6.6. Thailand
  • 9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 10.1. Major Players and Strategy Analysis
• 10.2. Market Share Analysis
• 10.3. Mergers, Acquisitions, Agreements, and Collaborations
• 10.4. Competitive Dashboard

11. COMPANY PROFILES

• 11.1. Avance Biosciences
• 11.2. Bio-Rad Laboratories, Inc.
• 11.3. JN medsys
• 11.4. Sigma-Aldrich
• 11.5. Precigenome LLC
• 11.6. QIAGEN N.V
• 11.7. STILLA TECHNOLOGIES
• 11.8. sysmex corporation
• 11.9. Thermo Fisher Scientific, Inc.

12. APPENDIX

• 12.1. Currency
• 12.2. Assumptions
• 12.3. Base and Forecast Years Timeline
• 12.4. Key Benefits for the Stakeholders
• 12.5. Research Methodology
• 12.6. Abbreviations